Novel Epigenetic Regulatory Mechanisms In Moraxella Catarrhalis And Non-typeable Haemophilus Influenzae: Impact On Vaccine Development And Role In Pathobiology
Funder
National Health and Medical Research Council
Funding Amount
$626,979.00
Summary
Moraxella catarrhalis (Mcat) and non-typeable Haemophilus influenzae (NTHI) are two major causes of middle ear infections in children, and respiratory disease in adults. This project aims to characterise novel regulatory mechanisms associated with disease isolates of these bacteria. This research will aid vaccine development by defining the repertoire of stably expressed potential vaccine targets of Mcat and NTHi, and will improve our understanding of host-pathogen interactions.
Phase Variable Protein Glycosylation In Bacteria Mucosal Pathogens And Its Role In Immune Evasion
Funder
National Health and Medical Research Council
Funding Amount
$409,728.00
Summary
The bacterium Haemophilus influenzae is a leading cause of ear infections. Hearing loss from these infections can seriously affect literacy and educational performance. As no vaccine is available, we will research how the bacterium makes the HMW protein that is important in infection. We will study how sugars are added to the surface of this protein so that the bacterium can escape the immune system, its role in related bacteria and how it may be used in a vaccine.
Determining The Bacterial Contributions To Tuberculosis And Identification Of Drug Targets
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Serious issues of drug resistance have emerged in tuberculosis prevention and are placing enormous pressure on global health systems. We have identified an enzyme of M. tuberculosis that is essential for its survival. This project will develop potent inhibitory compounds for this enzyme. Further, we will identify new drug targets through a screen to specifically identify the genes of the organism essential for its survival in the body. This information will be used to develop new TB drugs.
Worldwide Molecular Analysis Of Streptococcus Pyogenes Scarlet Fever Outbreaks
Funder
National Health and Medical Research Council
Funding Amount
$544,041.00
Summary
The microorganism group A Streptococcus (also called GAS or Streptococcus pyogenes) ranks among the top 10 infectious disease killers of humans. Recently, outbreaks of scarlet fever have occurred in both Asia and the United Kingdom, placing a serious strain on health systems. The reasons underlying these outbreaks remain unknown. Our team will lead the global effort to characterise this rise in scarlet fever, and provide recommendations and solutions to health professionals.
Protein Glycan Interactions In Infectious Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$9,182,220.00
Summary
Infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. This is a broad-based collaborative proposal, building on our previous achievements. Its aim is to better understand the dynamic interactions between major disease-causing microbes and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat infectious diseases in the 21st centu ....Infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. This is a broad-based collaborative proposal, building on our previous achievements. Its aim is to better understand the dynamic interactions between major disease-causing microbes and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat infectious diseases in the 21st century.Read moreRead less
Comparative And Functional Genomics Of Human Bacterial Pathogens
Funder
National Health and Medical Research Council
Funding Amount
$601,484.00
Summary
Bacteria have evolved different ways of causing disease in humans. Some bacteria produce toxins that attack the host or they have developed ways to persist in the host by evading immune responses and resisting antibiotics. This project is concerned with understanding how these processes occur and developing preventative strategies for two important groups of bacteria that cause disease in humans, including the bacteria that cause TB and the devastating skin disease Buruli ulcer, and the hospital ....Bacteria have evolved different ways of causing disease in humans. Some bacteria produce toxins that attack the host or they have developed ways to persist in the host by evading immune responses and resisting antibiotics. This project is concerned with understanding how these processes occur and developing preventative strategies for two important groups of bacteria that cause disease in humans, including the bacteria that cause TB and the devastating skin disease Buruli ulcer, and the hospital superbug "Golden Staph".Read moreRead less
Pathogenesis, Treatment And Prevention Of Bacterial Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$852,458.00
Summary
Bacterial infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. My research program aims to better understand the dynamic interactions between major disease-causing bacteria and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat bacterial infectious diseases in the 21st century.
Preclinical Studies Of Group A Streptococcal Vaccine Candidates
Funder
National Health and Medical Research Council
Funding Amount
$532,492.00
Summary
Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified 2 new protective candidate antigens, and we seek to undertake critical preclinical studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Wyeth) leading to human trials and the development of a safe group A streptococcal vaccine for human use.